saralasin and Glaucoma

saralasin has been researched along with Glaucoma* in 1 studies

Other Studies

1 other study(ies) available for saralasin and Glaucoma

ArticleYear
Glaucoma, capillaries and pericytes. 3. Peptide hormone binding and influence on pericytes.
    Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 1996, Volume: 210, Issue:5

    To test the potential for vasoactive neuropeptide receptors to affect capillary resistance, we have begun to study the plausibility that pericytes might be equipped to respond to a representative peptide vasoconstrictor and a representative peptide vasodilator. Pericytes cultured from the bovine retinal vasculature specifically bind the angiotensin II (Ang II) antagonist saralasin (1 nM125I-saralasin bound at 2.2 +/- 0.41 fmol/mg protein) and 125I-vasoactive intestinal peptide (VIP; Kd of 0.5 nM with a population of 30 fmol/mg protein). Incubation with 100 microM Ang II induced minimal cAMP synthesis, while VIP (1 microM, 10 microM) did not induce any change in cAMP concentration. Ang II (10 microM and 100 microM) caused contraction of pericytes cultured on an elastic silicone surface. Circulating or locally produced vasoactive neuropeptides might affect pericyte contractile tone via several intracellular pathways, moderated by indirect effects of these peptides through endothelial stimulation, with the net effect on local blood flow resulting from the effects on arteries and veins as well as capillaries.

    Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Binding Sites; Blood Flow Velocity; Capillaries; Capillary Resistance; Cattle; Cells, Cultured; Cyclic AMP; Glaucoma; Muscle Contraction; Muscle, Smooth, Vascular; Optic Nerve; Retinal Vessels; Saralasin; Vasoactive Intestinal Peptide; Vasoconstrictor Agents

1996